The Promise of Photobiomodulation in Combating Alzheimer's disease

Vaisitti García^*
*Correspondence: Vaisitti García, Department of Internal Medicine, Universidad Santiago de Cali, Cali 5183000, Colombia, Email:

Introduction

Alzheimer’s disease is one of the most debilitating neurodegenerative conditions affecting millions of people worldwide. Characterized by progressive memory loss, cognitive decline, and behavioral changes, AD is a significant public health challenge with no cure and limited treatment options. The global aging population, coupled with the rising prevalence of Alzheimer's, has made it a critical focus of medical research. As the search for effective therapies intensifies, scientists have turned to alternative treatment modalities, one of the most promising being Photobiomodulation (PBM) therapy. PBM, sometimes referred to as Low-Level Laser Therapy (LLLT) or red light therapy, involves the use of specific wavelengths of light to stimulate cellular function, promote healing, and reduce inflammation. Early research into the potential of PBM for treating neurological disorders, including Alzheimer’s disease, has shown encouraging results. This article explores the science behind PBM, its application in Alzheimer's disease, the mechanisms through which it may benefit patients, and the current state of research into its therapeutic potential [1].

Photobiomodulation (PBM) is a non-invasive treatment that uses light in the red or near-infrared spectrum (typically 600–1000 nm) to modulate cellular activity. The concept is based on the principle that light photons, when absorbed by cellular chromophores (particularly cytochrome c oxidase in mitochondria), can influence cellular metabolism, enhance energy production (ATP), and modulate inflammation and oxidative stress. These actions have been shown to facilitate tissue repair, reduce pain, and improve cognitive function in various contexts. The underlying mechanism of PBM revolves around its effect on mitochondrial activity. The mitochondria are responsible for generating ATP, which powers most cellular functions. When mitochondria absorb light energy, it is thought to enhance ATP production, improving cellular function and potentially reversing or mitigating dysfunctions that underlie various diseases, including Alzheimer's [2].

Description

Alzheimer's disease is the most common form of dementia, representing an estimated 60-80% of dementia cases globally. According to the World Health Organization, around 55 million people are living with dementia worldwide, with Alzheimer's accounting for a large proportion. The number of cases is expected to rise dramatically as the global population ages. By 2050, it is projected that the number of people with Alzheimer's will nearly triple, placing an overwhelming burden on healthcare systems, families, and society at large. Alzheimer's disease is primarily characterized by two hallmark pathological features in the brain: amyloid-beta plaques and tau tangles. Amyloid-beta plaques are abnormal clumps of protein that accumulate between nerve cells, disrupting communication and leading to neuroinflammation. Tau tangles, on the other hand, involve the accumulation of twisted tau protein within neurons, leading to cellular damage and death. The exact cause of Alzheimer’s is not fully understood, but factors such as genetics, age, inflammation, oxidative stress, and mitochondrial dysfunction have been implicated in the development and progression of the disease. Currently, there is no cure for Alzheimer’s, and available treatments primarily aim to alleviate symptoms and slow disease progression rather than address the underlying causes. This has spurred research into novel therapeutic approaches, one of which is photobiomodulation [3].

hotobiomodulation is thought to exert its therapeutic effects on Alzheimer's disease through several key mechanisms that target the root causes of neuronal damage and cognitive decline. The most well-documented effect of PBM is its ability to enhance mitochondrial function. In Alzheimer's, mitochondrial dysfunction is a significant factor contributing to neuronal damage and cell death. Neurons in Alzheimer's patients often show reduced ATP production, which impairs their ability to function properly. PBM therapy works by stimulating mitochondrial activity, leading to increased ATP production, which can help neurons restore their normal function. Enhanced ATP levels improve cellular communication, reduce oxidative stress, and support the repair of damaged brain cells. Oxidative stress is another key player in the pathophysiology of Alzheimer's disease. Reactive Oxygen Species (ROS) accumulate in the brain, leading to inflammation and neuronal damage. PBM has been shown to reduce oxidative stress by increasing the production of antioxidants, neutralizing harmful ROS, and reducing inflammation. This antioxidant effect can protect neurons from the damaging effects of oxidative stress, potentially slowing disease progression. Chronic inflammation in the brain, driven by activated microglia and astrocytes, is a hallmark of Alzheimer's disease. This neuroinflammation exacerbates the deposition of amyloid-beta plaques and tau tangles, further impairing neuronal function. PBM has been shown to reduce the activation of glial cells, thereby decreasing neuroinflammation. In preclinical models, PBM has demonstrated the ability to reduce the expression of pro-inflammatory cytokines, suggesting that it may play a role in attenuating the inflammatory response associated with Alzheimer's [4].

Photobiomodulation holds great promise as a non-invasive, safe, and potentially effective treatment for Alzheimer's disease. By targeting the underlying mechanisms of mitochondrial dysfunction, oxidative stress, inflammation, and protein aggregation, PBM has the potential to slow or even reverse cognitive decline in Alzheimer's patients. The current preclinical and clinical data suggest that PBM could be a valuable adjunct to existing therapies, offering a new avenue for treatment where conventional approaches have largely fallen short. However, despite the early positive results, there is still much to learn. Larger clinical trials with standardized protocols are necessary to confirm the therapeutic benefits of PBM in Alzheimer’s disease. Additionally, understanding the optimal treatment parameters, such as light wavelength, intensity, and frequency, will be critical to maximizing the efficacy of PBM. Given the growing burden of Alzheimer's disease and the limited efficacy of current treatments, it is essential that research into novel therapies like PBM continues. If future studies validate its effectiveness, PBM could become an important tool in the fight against Alzheimer's disease, offering hope to millions of patients and their families [5].

Conclusion

The potential of Photobiomodulation (PBM) as a therapeutic intervention for Alzheimer’s disease offers a promising new frontier in the fight against one of the most devastating neurodegenerative conditions of our time. As Alzheimer’s disease continues to pose a significant global health challenge, with millions of individuals affected and no cure currently available, the need for innovative treatment strategies has never been more urgent. PBM therapy, with its non-invasive approach and ability to stimulate cellular repair, reduce inflammation, enhance mitochondrial function, and modulate brain activity, holds considerable promise in addressing many of the underlying pathophysiological processes that contribute to Alzheimer's progression. Although the preclinical studies and early-phase clinical trials are encouraging, much remains to be understood about the optimal treatment parameters and the long-term safety and efficacy of PBM in Alzheimer's patients. Variability in study protocols, as well as the need for larger, more rigorous trials, means that PBM’s role in Alzheimer’s treatment is still in its early stages. However, the results to date provide a solid foundation for continued research and development.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Yang, Xiaoguang, Sholpan Askarova, Wenwen Sheng and J. K. Chen, et al. "Low energy laser light (632.8 nm) suppresses amyloid-β peptide-induced oxidative and inflammatory responses in astrocytes."Neurosci 171 (2010): 859-868.

Google Scholar, Crossref, Indexed at

2. Enengl, Joachim, Michael R. Hamblin and Peter Dungel. "Photobiomodulation for Alzheimer’s disease: Translating basic research to clinical application."J Alzheimers Dis 75 (2020): 1073-1082.

Google Scholar, Crossref, Indexed at

3. Wang, Pengbo and Ting Li. "Which wavelength is optimal for transcranial low‐level laser stimulation?."J Biophotonics 12 (2019): e201800173.

Google Scholar, Crossref, Indexed at

4. Purushothuman, Sivaraman, Daniel M. Johnstone, Charith Nandasena and John Mitrofanis, et al. "Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex-evidence from two transgenic mouse models." Alzheimer’s Res Ther6 (2014): 1-13.

Google Scholar, Crossref, Indexed at

5. Tao, Lechan, Qi Liu, Fuli Zhang and Yuting Fu, et al. "Microglia modulation with 1070-nm light attenuates Aβ burden and cognitive impairment in Alzheimer’s disease mouse model."Light Sci Appl 10 (2021): 179.

Google Scholar, Crossref, Indexed at